Asia-Pacific Type 2 Diabetes Mellitus Treatment Market Will Exceed $10 Billion by 2021

Date: 2016-02-18

The treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%.

Aswini Nath, Senior Analyst for GBI Research, says: “T2DM is becoming an increasingly common problem in APAC regions as they become more industrialized and diets become more Westernized. In line with this, there is a very large and innovative pipeline, suggesting a strong potential for unmet needs to be addressed in coming years.

“The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes in comparison to currently marketed products. This suggests that unmet needs relating to patient convenience and ease of use will be addressed most significantly over the forecast period.”

GBI Research also states that the recently approved drug classes, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, are expected to increase their market share by 2021.

Nath continues: “In comparison to many previously marketed therapies, the new drug classes provide beneficial effects such as improved weight control and lowered hypoglycemia risk. Furthermore, a recent study also identified cardiovascular risk reduction with Jardiance, an SGLT-2 inhibitor.

“These treatments have already achieved strong market uptake, which is expected to increase over the forecast period. The recently launched products in the APAC region that are expected to contribute most significantly to market growth include Forxiga, Invokana, and Jardiance; DPP-4 inhibitors – Zafatek, and Tenglyn/Ziten.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample